Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Non-Myeloablative PBSC Transplant for Metastatic Renal Cell Carcinoma
NCT00005851Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Feb 2000
- Primary completion
- Jul 2004
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of donor lymphocyte infusion in renal cell carcinoma (RCC), sponsored by Fred Hutchinson Cancer Center. Primary endpoints: True response rate (complete response [CR] or partial response [PR]) at 5 years, Transplant-related mortality at 200 days and 1 more. Started Feb 2000; status: completed.
02
Drugs
donor lymphocyte infusion
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00005851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005851.